aTyr Pharma, Inc. (ATYR)
| Market Cap | 52.97M -89.5% |
| Revenue (ttm) | 190,000 -19.1% |
| Net Income | -60.81M |
| EPS | -0.62 |
| Shares Out | 98.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 266,253 |
| Open | 0.5600 |
| Previous Close | 0.5546 |
| Day's Range | 0.5300 - 0.5650 |
| 52-Week Range | 0.3950 - 6.5000 |
| Beta | 0.52 |
| Analysts | Buy |
| Price Target | 2.86 (+429.63%) |
| Earnings Date | Aug 7, 2026 |
About ATYR
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pn... [Read more]
Financial Performance
In 2025, aTyr Pharma's revenue was $190,000, a decrease of -19.15% compared to the previous year's $235,000. Losses were -$74.12 million, 15.8% more than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for ATYR stock is "Buy." The 12-month stock price target is $2.86, which is an increase of 429.63% from the latest price.
News
Ethos to Present at the Goldman Sachs Communacopia + Technology Conference
AUSTIN, Texas, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ: LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder ...
Ethos Signs Erin Andrews as Its Next Sports Partner in Growing Campaign to Make Life Insurance Accessible for Every Family
AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced that it has sig...
aTyr Pharma reports Q2 EPS (11c), consensus (13c)
Cash, cash equivalents, restricted cash and available-for-sale investments as of June 30, 2026, were $58.9 million. Based on its current cash and new operating expense forecast and plans, the Company…
aTyr Pharma announces restructuring, will lay off roughly 60% of workforce
aTyr Pharma (ATYR) announced second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program in interstitial lung disease, including pulmonary sarcoidosis and systemic ...
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. Workforce reduction of approximately...
aTyr Pharma Quarterly report: Q2 2026
aTyr Pharma has published its Q2 2026 quarterly earnings report on August 7, 2026.
aTyr Pharma Earnings release: Q2 2026
aTyr Pharma released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Ethos Reports Second Quarter Fiscal Year 2026 Financial Results
Q2 Revenue grew 113 % year-over-year to $ 190 million Q2 Direct Channel Revenue grew 131 % year-over-year to $ 116 million Q2 Third-Party Revenue grew 90 % year-over-year to $ 73 million Board of Dire...
Ethos and North American Expand Their Indexed Universal Life Product Offering to include Children
AUSTIN, Texas and DES MOINES, Iowa, July 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced the expan...
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to F...
Ethos to Announce Second Quarter 2026 Financial Results on August 3, 2026
AUSTIN, Texas, July 02, 2026 (GLOBE NEWSWIRE) -- Ethos Technologies Inc. (NASDAQ: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announc...
aTyr Pharma Transcript: Life Sciences Virtual Investor Forum
Revised summary: Efzofitimod showed quality of life improvements and a strong safety profile in pulmonary sarcoidosis, despite missing the primary steroid reduction endpoint. The next phase III trial will target a sicker population with forced vital capacity as the primary endpoint, aiming for approval and expansion to other interstitial lung diseases.
aTyr Pharma Transcript: Jefferies Global Healthcare Conference 2026
Efzofitimod showed strong, durable benefits in pulmonary sarcoidosis, especially for restrictive patients, with significant improvements in quality of life and lung function. A new phase III trial will focus on FVC as the primary endpoint, targeting a high-need population and leveraging increased drug exposure for greater efficacy.
Forget the SpaceX IPO. These 2 New Stocks Stand Out Right Now.
Recent IPOs Pattern Group and Ethos Technologies are showing constructive technical patterns even as investors continue waiting for a SpaceX public offering.
Ethos Partners with Baseball Legend David Ortiz to Champion Life Insurance as a Family Financial Essential
AUSTIN, Texas, May 21, 2026 (GLOBE NEWSWIRE) -- Ethos, a leading life insurance technology company on a mission to democratize access to life insurance, today announced a new partnership with baseball...
aTyr Pharma upgraded to Buy from Hold at Freedom Broker
Freedom Broker upgraded aTyr Pharma (ATYR) to Buy from Hold with a price target of $3.50, up from $1. The firm says much of the uncertainty following the EFZO-FIT study…
Ethos to Present at Upcoming Investor Conferences
AUSTIN, Texas, May 15, 2026 (GLOBE NEWSWIRE) -- Ethos (NASDAQ: LIFE), a leading life insurance technology company democratizing access to life insurance, today announced that Peter Colis, Co-founder a...
aTyr Pharma reports Q1 EPS (11c), consensus (15c)
“2026 is off to a productive start, as we now have a clear path forward for efzofitimod in pulmonary sarcoidosis, a major form of interstitial lung disease, following our recent…
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patient...
aTyr Pharma Quarterly report: Q1 2026
aTyr Pharma has published its Q1 2026 quarterly earnings report on May 15, 2026.
aTyr Pharma Earnings release: Q1 2026
aTyr Pharma released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Ethos Announces Early Lock-Up Release
AUSTIN, Texas--(BUSINESS WIRE)--Ethos Announces Early Lock-Up Release.
aTyr Pharma to Participate in Upcoming Investor Conferences
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its propr...
aTyr Pharma provides regulatory update on efzofitimod following Type C meeting
aTyr Pharma (ATYR) announced the path forward for efzofitimod, in pulmonary sarcoidosis, following the receipt of the official meeting minutes from a Type C meeting with the FDA. The purpose…
aTyr Pharma Transcript: Study update
A new phase III trial for efzofitimod in pulmonary sarcoidosis will focus on patients with restrictive lung disease, using FVC as the primary endpoint and an optimized dosing schedule. The study aims to enroll 372 patients globally, targeting a multi-billion dollar market opportunity.